Evidence map›Paper›PMID 30419879›Full record

ArticleBMC endocrine disorders2018

Short stature as a presenting symptom of attenuated Mucopolysaccharidosis type I: case report and clinical insights.

Ana Maria Martins, Kristin Lindstrom, Sandra Obikawa Kyosen, Maria Veronica Munoz-Rojas, Nathan Thibault, Lynda E Polgreen

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC endocrine disorders, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Observational
  5. Article
  6. Review
  7. Diagnosis of Mucopolysaccharidoses.Diagnostics (Basel, Switzerland) · 2020
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Ana Maria MartinsUniversidade Federal de São Paulo, São Paulo, Brazil.
Kristin LindstromPhoenix Children's Hospital, Phoenix, AZ, USA.
Sandra Obikawa KyosenUniversidade Federal de São Paulo, São Paulo, Brazil.
Maria Veronica Munoz-RojasSanofi Genzyme, Cambridge, MA, USA.
Nathan ThibaultSanofi Genzyme, Cambridge, MA, USA.
Lynda E PolgreenLos Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 West Carson Street, Liu Research Building, Torrance, CA, 90502, USA. lpolgreen@labiomed.org.
Sanofi (United States) · USUniversidade Federal de São Paulo · BRPhoenix Children's Hospital · USThe Lundquist Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMucopolysaccharidosis type I (MPS I) results in significant disease burden and early treatment is important for optimal outcomes. Recognition of short stature and growth failure as symptoms of MPS I among pediatric endocrinologists may lead to earlier diagnosis and treatment. CASE PRESENTATION: A male patient first began experiencing hip pain at 5 years of age and was referred to an endocrinologist for short stature at age 7. Clinical history included recurrent respiratory infections, sleep apnea, moderate joint contractures, mild facial dysmorphic features, scoliosis, and umbilical hernia. Height was more than - 2 SD below the median at all time points. Growth velocity was below the 3rd percentile. Treatment for short stature included leuprolide acetate and recombinant human growth hormone. The patient was diagnosed with MPS I and began enzyme replacement therapy with laronidase at age 18.

conclusionsThe case study patient had many symptoms of MPS I yet remained undiagnosed for 11 years after presenting with short stature. The appropriate path to MPS I diagnosis when patients present with short stature and/or growth failure plus one or more of the common signs of attenuated disease is described. Improved awareness regarding association of short stature and growth failure with attenuated MPS I is needed since early identification and treatment significantly decreases disease burden.

Indexed as

AdolescentChildChild, PreschoolDiagnosis, DifferentialDwarfismHumansMaleMucopolysaccharidosis IEarly diagnosisGrowth delayMPS I diagnosisMPS I signs and symptomsPhysician awarenessShort stature

Identifiers

PMID30419879
PMCPMC6233567
OpenAlexW2900583203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.